Live: Will Intuitive Surgical Smash Tonight’s Q2 Earnings After 29% YTD Decline?

That wraps up our initial coverage of Intuitive Surgical’s Q2 results. Thank you for stopping by!

Intuitive Surgical (NASDAQ:ISRG) is down 7.5% after Q2 earnings.

Does the Reaction Fit the Results?

The company reported a strong beat: +11.83% on EPS, revenue up 18.54%, and non-GAAP gross margin expanding to 70.0% from 67.9%.

The gross margin guidance was raised to 68.0%–69.0%, directly refuting fears about the da Vinci 5 margin.

Historical Context

Prior beats averaged a +3.48% day-of move, so today matches the pattern. Yet Q1 2026 popped +7.16% then faded -9.41% over 30 days.

What the Market Is Watching

Procedure guidance was held at 13.5%–15.5%, not raised, which might be a concern that drove the sell-off.

Demand for Intuitive Surgical’s newest robotic system remained strong, with da Vinci 5 placements increasing 37% year over year to 246.

Total da Vinci placements rose 18% to 468, helping systems revenue increase 19% to $685 million.

More than half of da Vinci placements used operating leases, including 131 usage-based systems. This structure could limit upfront systems revenue but expand recurring revenue as utilization grows.

Intuitive Surgical now has 11,710 da Vinci systems installed worldwide, up 12% from one year ago.

Intuitive Surgical delivered a strong second quarter, with revenue increasing 19% to $2.89 billion and adjusted EPS climbing 28% to $2.80.

Both figures exceeded Wall Street’s expectations, although EPS included an $0.08 benefit from refunds of tariffs paid in prior periods.

Total procedures increased 16% year over year, including 15% growth for da Vinci procedures and 36% growth for Ion procedures.

Management continues to expect full-year da Vinci procedure growth of 13.5% to 15.5%, likely near the midpoint of that range.

Intuitive Surgical just reported earnings, with shares initially down 7% following the report. Here are the key numbers:

• Revenue: $2.89 billion vs. $2.83 billion expected
• Adjusted EPS: $2.80 vs. $2.50 expected

Guidance:

• Worldwide da Vinci procedure growth: 13.5% to 15.5%
• Non-GAAP gross margin: 68.0% to 69.0%
• Non-GAAP operating expense growth: 11% to 13%

Quick Read:

Intuitive Surgical comfortably beat expectations, with revenue rising 18.4% and adjusted EPS climbing 27.9% year over year.

Despite the beat, shares are falling as investors focus on the procedure-growth outlook and whether future growth can justify the stock’s premium valuation.

Bull Case

• Beat streak intact: Four consecutive EPS beats, capped by Q1’s $2.50 vs. $2.1068 earnings report.
• da Vinci 5 momentum: 232 placements in Q1 with 11% higher utilization than Xi.
• Recurring engine: Instruments & accessories revenue reached $1.69 billion, +23%, backed by $7.98 billion cash.
• Sentiment lean: Composite score 65.03 (Bullish); average analyst price target of $558.01 vs current share price of $401.96.

Bear Case

• Post-beat fade: Average 30-day change of -2.28% after prior beats.
• Margin compression: 1.0% tariff drag; gross margin guide 67.5%-68.5%.
• Macro chill: Consumer sentiment at 44.8 threatens hospital capex.
• Valuation reset: P/E of 49 with the stock down 31.32% YTD.

The current full-year framework for Intuitive Surgical (NASDAQ:ISRG) calls for 13.5% to 15.5% da Vinci procedure growth and a 67.5% to 68.5% non-GAAP gross margin, embedding a 1.0% tariff drag.

Management historically guides conservatively, then walks the range up: 2025 started at 15.5%–17% and ended at 18%.

Polymarket’s crowd assigns a 46.5% probability to Q2 procedure growth landing in the 15%–17.5% range, with 34.5% for a sub-15% result.

Bullish scenario: full-year procedure guide raised above 15.5%, margin biased toward 68%+, and softer tariff commentary.

Bearish scenario: unchanged procedure range, margin drift toward 67.5%, and hospital capex caution.

With four straight EPS beats averaging 18.66% most recently, the headline number matters less than the raise.

With Intuitive Surgical (NASDAQ:ISRG) set to report Q2 earnings tonight shortly after 4:00 PM ET, here’s the framework for tonight’s call.

Top 5 Analyst Questions

• Does FY2026 da Vinci procedure guidance of 13.5%–15.5% get raised after crowd bets favor 15%–17.5% growth?
• Any read-through from HCA’s July 14 surgical volume warning?
• Is the 1.0% tariff drag holding?
• da Vinci 5 mix and ASP trajectory after 232 placements in Q1?
• Buyback pace after $1.1B repurchased in Q1?

Key Topics and Buzzwords

• Listen for: “quintuple aim,” “installed base leverage,” “usage-based leasing,” “capital constrained customers,” force feedback EU approval.
• Ion sustainability after 39% Q1 procedure growth; direct sales transition in Italy, Spain, Portugal.

Red Flags

• Procedure miss versus guide, tariff drag expansion, gross margin cut below 67.5%, Hugo/Ottava share commentary, or hospital capex softness.

This live blog is being updated by Thomas Richmond, a 24/7 Wall St. contributor. You’ll get expert analysis of Intuitive Surgical’s Q2 earnings.

Simply stay on this page, and new updates will appear below automatically. We expect Intuitive Surgical to release earnings shortly after 4:00 p.m. ET.

Intuitive Surgical’s (NASDAQ: ISRG) second-quarter report tonight will test whether the company can defend its premium valuation as procedure growth slows and tariffs pressure margins.

The biggest number to watch is procedure growth. After expanding 18% in 2025, management currently expects growth of 13.5% to 15.5% in fiscal 2026.

Investors will also be watching the mix of da Vinci 5 placements and utilization gains, which could determine the strength of the systems revenue narrative heading into the second half.

Management has estimated that tariffs will result in a drag equal to approximately 1% of revenue due to exposure across Mexico, Germany, and China. Any additional pressure could weigh on gross margins.

Shares have declined 21.92% over the past year. A guidance increase tonight could reinvigorate the growth-at-a-reasonable-price case, but a reduction in margin estimates would likely cement the stock’s ongoing derating.